Scienture says large national health plan adds REZENOPY naloxone spray to formulary

Scienture Holdings, Inc.

Scienture Holdings, Inc.

SCNX

0.00
  • Scienture secured formulary coverage for REZENOPY naloxone 10 mg nasal spray with a large national health plan.
  • Coverage spans commercial insurance, Medicare supplemental plans, extending access to more than 100 million covered lives ahead of a mid-July launch.
  • Prior GPO agreements provide access across more than 5,000 healthcare facilities, covering about 60% of the institutional GPO market.
  • IQVIA data show the U.S. naloxone market at about $144 million in annual sales on 9,800,000 units.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scienture Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606090805PRIMZONEFULLFEED9733783) on June 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.